| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Methylation | 18 | 2024 | 697 | 1.770 |
Why?
|
| Proto-Oncogene Proteins | 9 | 2023 | 666 | 0.730 |
Why?
|
| Herpesvirus 4, Human | 5 | 2023 | 122 | 0.660 |
Why?
|
| CpG Islands | 11 | 2024 | 168 | 0.650 |
Why?
|
| Cytosine | 5 | 2015 | 121 | 0.620 |
Why?
|
| Restriction Mapping | 2 | 2018 | 120 | 0.610 |
Why?
|
| Oncogene Proteins, Fusion | 8 | 2023 | 134 | 0.600 |
Why?
|
| DNA-Binding Proteins | 8 | 2023 | 1234 | 0.510 |
Why?
|
| Sequence Analysis, DNA | 3 | 2018 | 893 | 0.490 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2018 | 537 | 0.490 |
Why?
|
| Epigenesis, Genetic | 10 | 2023 | 555 | 0.480 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 3 | 2022 | 29 | 0.460 |
Why?
|
| Mixed Function Oxygenases | 5 | 2023 | 68 | 0.450 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2018 | 423 | 0.440 |
Why?
|
| Erythroid Cells | 1 | 2013 | 16 | 0.410 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2023 | 59 | 0.410 |
Why?
|
| Erythropoiesis | 1 | 2013 | 53 | 0.410 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 10 | 2023 | 60 | 0.400 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2013 | 166 | 0.380 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2025 | 87 | 0.380 |
Why?
|
| Hematologic Neoplasms | 2 | 2014 | 372 | 0.370 |
Why?
|
| Colonic Neoplasms | 3 | 2023 | 579 | 0.370 |
Why?
|
| Leukemia | 4 | 2023 | 301 | 0.350 |
Why?
|
| Dioxygenases | 5 | 2021 | 82 | 0.340 |
Why?
|
| Colorectal Neoplasms | 3 | 2024 | 1053 | 0.330 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2018 | 1338 | 0.320 |
Why?
|
| Embryonic Stem Cells | 3 | 2019 | 87 | 0.310 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2025 | 636 | 0.300 |
Why?
|
| Mutation | 9 | 2025 | 4272 | 0.290 |
Why?
|
| Virus Latency | 4 | 2023 | 31 | 0.280 |
Why?
|
| Cell Line, Tumor | 12 | 2025 | 2755 | 0.270 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2024 | 282 | 0.260 |
Why?
|
| 5-Methylcytosine | 5 | 2015 | 121 | 0.260 |
Why?
|
| Genome, Viral | 3 | 2022 | 77 | 0.250 |
Why?
|
| Aging | 3 | 2023 | 727 | 0.250 |
Why?
|
| Humans | 48 | 2025 | 93511 | 0.250 |
Why?
|
| Chromatin | 4 | 2023 | 440 | 0.240 |
Why?
|
| CCCTC-Binding Factor | 3 | 2023 | 20 | 0.240 |
Why?
|
| Neoplasm, Residual | 3 | 2005 | 196 | 0.240 |
Why?
|
| Haploinsufficiency | 2 | 2025 | 69 | 0.230 |
Why?
|
| Transcriptional Activation | 2 | 2024 | 290 | 0.230 |
Why?
|
| RNA | 4 | 2024 | 573 | 0.220 |
Why?
|
| Homologous Recombination | 1 | 2025 | 57 | 0.210 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2019 | 665 | 0.210 |
Why?
|
| Mice | 13 | 2024 | 12269 | 0.210 |
Why?
|
| Animals | 19 | 2024 | 28155 | 0.210 |
Why?
|
| Transcription Factors | 6 | 2024 | 1691 | 0.210 |
Why?
|
| BRCA1 Protein | 1 | 2025 | 214 | 0.200 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2016 | 107 | 0.190 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 1173 | 0.190 |
Why?
|
| Databases, Genetic | 1 | 2024 | 282 | 0.190 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2023 | 98 | 0.190 |
Why?
|
| Drug Overdose | 1 | 2023 | 89 | 0.180 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2024 | 454 | 0.180 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2024 | 188 | 0.180 |
Why?
|
| Paraganglioma | 1 | 2022 | 15 | 0.180 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2023 | 155 | 0.180 |
Why?
|
| Pheochromocytoma | 1 | 2022 | 53 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2024 | 365 | 0.170 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 2303 | 0.170 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2022 | 65 | 0.170 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2022 | 83 | 0.170 |
Why?
|
| Neuroendocrine Tumors | 1 | 2023 | 136 | 0.160 |
Why?
|
| Adenoma | 1 | 2023 | 258 | 0.160 |
Why?
|
| Carcinogenesis | 2 | 2023 | 235 | 0.160 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 308 | 0.160 |
Why?
|
| Transcription, Genetic | 4 | 2022 | 1117 | 0.160 |
Why?
|
| Bacteria | 1 | 2024 | 509 | 0.160 |
Why?
|
| WT1 Proteins | 2 | 2014 | 21 | 0.160 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 456 | 0.160 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2018 | 826 | 0.160 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 233 | 0.160 |
Why?
|
| DNA Primers | 2 | 2016 | 531 | 0.160 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2018 | 170 | 0.150 |
Why?
|
| Gene Expression | 3 | 2022 | 1301 | 0.150 |
Why?
|
| Transcriptome | 2 | 2022 | 762 | 0.150 |
Why?
|
| Breast | 1 | 2021 | 294 | 0.150 |
Why?
|
| Esophageal Neoplasms | 1 | 2022 | 344 | 0.150 |
Why?
|
| Breast Neoplasms | 2 | 2025 | 3110 | 0.150 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2023 | 378 | 0.150 |
Why?
|
| Cell Cycle Proteins | 1 | 2022 | 409 | 0.150 |
Why?
|
| DNA Repair | 1 | 2021 | 361 | 0.150 |
Why?
|
| Azacitidine | 2 | 2023 | 149 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2011 | 887 | 0.150 |
Why?
|
| Viral Matrix Proteins | 1 | 2018 | 13 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2018 | 7 | 0.150 |
Why?
|
| Chromosome Mapping | 1 | 2022 | 1052 | 0.140 |
Why?
|
| Sex Characteristics | 2 | 2019 | 333 | 0.140 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2018 | 42 | 0.140 |
Why?
|
| Ganglia, Spinal | 1 | 2018 | 72 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2025 | 797 | 0.140 |
Why?
|
| Neuralgia | 1 | 2018 | 27 | 0.140 |
Why?
|
| Oncogenes | 1 | 2018 | 100 | 0.140 |
Why?
|
| Caloric Restriction | 1 | 2017 | 13 | 0.130 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2017 | 41 | 0.130 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2015 | 23 | 0.130 |
Why?
|
| Phthalazines | 3 | 2025 | 53 | 0.130 |
Why?
|
| Microbiota | 1 | 2022 | 425 | 0.130 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2024 | 590 | 0.130 |
Why?
|
| Sex Chromosomes | 1 | 2017 | 56 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 715 | 0.130 |
Why?
|
| DNA Modification Methylases | 1 | 2016 | 32 | 0.130 |
Why?
|
| Heart | 1 | 2019 | 522 | 0.120 |
Why?
|
| Immunologic Memory | 1 | 2017 | 184 | 0.120 |
Why?
|
| Neoplasms, Experimental | 1 | 2017 | 263 | 0.120 |
Why?
|
| Piperazines | 3 | 2025 | 284 | 0.120 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2015 | 295 | 0.120 |
Why?
|
| Leukemia, Myeloid | 3 | 2010 | 240 | 0.120 |
Why?
|
| Binding Sites | 4 | 2023 | 1133 | 0.120 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2018 | 190 | 0.110 |
Why?
|
| Chronic Pain | 1 | 2018 | 185 | 0.110 |
Why?
|
| Gene Expression Regulation, Viral | 3 | 2022 | 87 | 0.110 |
Why?
|
| Up-Regulation | 5 | 2018 | 730 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2023 | 457 | 0.110 |
Why?
|
| Macaca mulatta | 1 | 2017 | 448 | 0.110 |
Why?
|
| Phenotype | 4 | 2024 | 2544 | 0.110 |
Why?
|
| RNA Interference | 2 | 2018 | 379 | 0.110 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 52 | 0.110 |
Why?
|
| DNA | 4 | 2023 | 1265 | 0.110 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 555 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2022 | 3502 | 0.100 |
Why?
|
| DNA Mutational Analysis | 2 | 2012 | 543 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 641 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2015 | 297 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 660 | 0.100 |
Why?
|
| Antigens, CD34 | 1 | 2013 | 161 | 0.100 |
Why?
|
| Female | 15 | 2025 | 48698 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 4 | 2018 | 962 | 0.100 |
Why?
|
| Blood Donors | 1 | 2012 | 24 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2014 | 331 | 0.090 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2013 | 61 | 0.090 |
Why?
|
| Colon | 1 | 2015 | 540 | 0.090 |
Why?
|
| Male | 14 | 2024 | 44553 | 0.090 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2015 | 99 | 0.090 |
Why?
|
| Thrombocytopenia | 1 | 2012 | 189 | 0.090 |
Why?
|
| Histones | 1 | 2013 | 361 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2011 | 319 | 0.080 |
Why?
|
| Mice, Inbred NOD | 2 | 2024 | 216 | 0.080 |
Why?
|
| Myeloid Cells | 1 | 2011 | 119 | 0.080 |
Why?
|
| Blood Platelet Disorders | 1 | 2010 | 12 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 4 | 2018 | 3435 | 0.080 |
Why?
|
| Child, Preschool | 6 | 2017 | 3829 | 0.080 |
Why?
|
| Neuroblastoma | 1 | 2014 | 396 | 0.080 |
Why?
|
| Infant, Newborn | 4 | 2017 | 2479 | 0.080 |
Why?
|
| Cell Line | 3 | 2019 | 2464 | 0.080 |
Why?
|
| Cell Cycle | 3 | 2010 | 515 | 0.080 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2012 | 379 | 0.070 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2850 | 0.070 |
Why?
|
| Hematopoiesis | 3 | 2015 | 183 | 0.070 |
Why?
|
| Cell Survival | 1 | 2010 | 1004 | 0.070 |
Why?
|
| Host-Pathogen Interactions | 2 | 2022 | 240 | 0.070 |
Why?
|
| Infant | 4 | 2017 | 3220 | 0.070 |
Why?
|
| B-Lymphocytes | 3 | 2022 | 701 | 0.070 |
Why?
|
| Child | 7 | 2017 | 7355 | 0.070 |
Why?
|
| RUNX1 Translocation Partner 1 Protein | 2 | 2023 | 8 | 0.060 |
Why?
|
| Leukemia, Lymphoid | 1 | 2007 | 48 | 0.060 |
Why?
|
| Neoplasms | 2 | 2024 | 3169 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2007 | 26 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 3 | 2006 | 894 | 0.060 |
Why?
|
| Lymphopoiesis | 1 | 2007 | 47 | 0.060 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2006 | 18 | 0.060 |
Why?
|
| RNA, Neoplasm | 2 | 2004 | 86 | 0.060 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2006 | 29 | 0.060 |
Why?
|
| Gene Expression Regulation | 3 | 2022 | 1985 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 939 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 1587 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2024 | 2495 | 0.060 |
Why?
|
| Fetal Blood | 1 | 2006 | 95 | 0.060 |
Why?
|
| Alleles | 2 | 2024 | 1139 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2022 | 1660 | 0.060 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 266 | 0.060 |
Why?
|
| Sp1 Transcription Factor | 1 | 2024 | 24 | 0.050 |
Why?
|
| Protein Binding | 2 | 2022 | 1534 | 0.050 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2025 | 72 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2011 | 2026 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 1914 | 0.050 |
Why?
|
| Aspartate-Ammonia Ligase | 1 | 2004 | 2 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2005 | 174 | 0.050 |
Why?
|
| Rad51 Recombinase | 1 | 2025 | 81 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2005 | 140 | 0.050 |
Why?
|
| Asparaginase | 1 | 2004 | 35 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2005 | 1170 | 0.050 |
Why?
|
| Bacteroides fragilis | 1 | 2024 | 46 | 0.050 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 1518 | 0.050 |
Why?
|
| Nuclear Proteins | 2 | 2018 | 740 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2007 | 443 | 0.050 |
Why?
|
| Naloxone | 1 | 2023 | 72 | 0.050 |
Why?
|
| Ribonucleotides | 1 | 2023 | 13 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2024 | 271 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2005 | 476 | 0.050 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2023 | 14 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2023 | 30 | 0.050 |
Why?
|
| Acute Disease | 3 | 2012 | 841 | 0.050 |
Why?
|
| Fentanyl | 1 | 2023 | 86 | 0.050 |
Why?
|
| Entropy | 1 | 2023 | 42 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2003 | 54 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2003 | 63 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2023 | 92 | 0.050 |
Why?
|
| Cell Proliferation | 3 | 2018 | 1741 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2022 | 82 | 0.050 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2018 | 132 | 0.050 |
Why?
|
| Nuclear Lamina | 1 | 2022 | 7 | 0.050 |
Why?
|
| Lamin Type A | 1 | 2022 | 26 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2003 | 248 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 7061 | 0.040 |
Why?
|
| Haplotypes | 1 | 2024 | 647 | 0.040 |
Why?
|
| Esophagus | 1 | 2022 | 113 | 0.040 |
Why?
|
| Genome, Human | 2 | 2018 | 823 | 0.040 |
Why?
|
| Methyltransferases | 1 | 2023 | 213 | 0.040 |
Why?
|
| Aged | 4 | 2024 | 20430 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2017 | 2121 | 0.040 |
Why?
|
| Plasmids | 1 | 2022 | 273 | 0.040 |
Why?
|
| Epithelium | 1 | 2022 | 316 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2017 | 784 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 305 | 0.040 |
Why?
|
| Genotype | 2 | 2021 | 1866 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2021 | 98 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2021 | 254 | 0.040 |
Why?
|
| Ligands | 1 | 2022 | 476 | 0.040 |
Why?
|
| Stem Cells | 1 | 2023 | 387 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 198 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1448 | 0.040 |
Why?
|
| Adolescent | 3 | 2017 | 9606 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2022 | 392 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2021 | 172 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 526 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2015 | 1931 | 0.040 |
Why?
|
| Middle Aged | 4 | 2024 | 27569 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 513 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2015 | 1621 | 0.040 |
Why?
|
| Clone Cells | 2 | 2010 | 219 | 0.030 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 69 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2018 | 89 | 0.030 |
Why?
|
| Prognosis | 3 | 2018 | 3910 | 0.030 |
Why?
|
| DNA Restriction Enzymes | 1 | 2018 | 76 | 0.030 |
Why?
|
| Genomic Library | 1 | 2018 | 30 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2022 | 700 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2005 | 4560 | 0.030 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2018 | 61 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 151 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2018 | 422 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 554 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 208 | 0.030 |
Why?
|
| Epigenomics | 1 | 2018 | 109 | 0.030 |
Why?
|
| K562 Cells | 1 | 2017 | 48 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 873 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2022 | 1353 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 848 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2012 | 3054 | 0.030 |
Why?
|
| Longevity | 1 | 2017 | 60 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 120 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 317 | 0.030 |
Why?
|
| Histone Demethylases | 1 | 2016 | 34 | 0.030 |
Why?
|
| Myocytes, Cardiac | 1 | 2019 | 313 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2018 | 215 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 139 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2017 | 295 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2017 | 517 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 315 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2017 | 260 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 366 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2003 | 3828 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 1245 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2018 | 506 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1264 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2017 | 1133 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2015 | 96 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2017 | 696 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2014 | 22 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 306 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 76 | 0.030 |
Why?
|
| Immunoglobulins | 2 | 2005 | 122 | 0.030 |
Why?
|
| Immunophenotyping | 2 | 2005 | 224 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 603 | 0.030 |
Why?
|
| Models, Biological | 1 | 2021 | 1768 | 0.030 |
Why?
|
| Response Elements | 1 | 2014 | 65 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2014 | 259 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2007 | 1028 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2014 | 187 | 0.020 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2012 | 12 | 0.020 |
Why?
|
| Adult | 3 | 2018 | 27918 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2005 | 424 | 0.020 |
Why?
|
| Telomerase | 1 | 2012 | 67 | 0.020 |
Why?
|
| Rats | 1 | 2018 | 4072 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2005 | 712 | 0.020 |
Why?
|
| Recurrence | 2 | 2005 | 1190 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2011 | 84 | 0.020 |
Why?
|
| Family | 1 | 2012 | 324 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2011 | 177 | 0.020 |
Why?
|
| United States | 1 | 2023 | 7619 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2010 | 47 | 0.020 |
Why?
|
| Family Health | 1 | 2010 | 153 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 352 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 361 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2003 | 9098 | 0.020 |
Why?
|
| Exons | 1 | 2010 | 450 | 0.020 |
Why?
|
| Pedigree | 1 | 2010 | 961 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2002 | 1922 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2010 | 381 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 2220 | 0.020 |
Why?
|
| Granzymes | 1 | 2007 | 94 | 0.020 |
Why?
|
| Tandem Repeat Sequences | 1 | 2006 | 31 | 0.020 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2006 | 77 | 0.010 |
Why?
|
| Czech Republic | 1 | 2005 | 3 | 0.010 |
Why?
|
| CD13 Antigens | 1 | 2005 | 5 | 0.010 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2005 | 8 | 0.010 |
Why?
|
| Lewis X Antigen | 1 | 2005 | 9 | 0.010 |
Why?
|
| Gene Duplication | 1 | 2006 | 128 | 0.010 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2005 | 29 | 0.010 |
Why?
|
| GPI-Linked Proteins | 1 | 2005 | 55 | 0.010 |
Why?
|
| Neonatal Screening | 1 | 2006 | 66 | 0.010 |
Why?
|
| Neprilysin | 1 | 2005 | 39 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2006 | 264 | 0.010 |
Why?
|
| Glycosylation | 1 | 2005 | 137 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 2544 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2005 | 278 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2005 | 168 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 2465 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 537 | 0.010 |
Why?
|
| Air Movements | 1 | 2002 | 2 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 2002 | 23 | 0.010 |
Why?
|
| Equipment Failure Analysis | 1 | 2002 | 88 | 0.010 |
Why?
|
| Quality Control | 1 | 2002 | 123 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2004 | 409 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2005 | 664 | 0.010 |
Why?
|
| Temperature | 1 | 2002 | 424 | 0.010 |
Why?
|
| Apoptosis | 1 | 2007 | 1721 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 1713 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 2715 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 5410 | 0.010 |
Why?
|